NCT07194382View on ClinicalTrials.gov

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

AP02

Oral inhalation solution

DRUG

Placebo

Placebo oral inhalation solution

Sponsors

Lead Sponsor

Avalyn Pharma Inc.
All Listed Sponsors
lead

Avalyn Pharma Inc.

INDUSTRY